 | | Vol. 14.18 – 12 May, 2022 |
| |
|
|
CDK12 Promotes Tumorigenesis but Induces Vulnerability to Therapies Inhibiting Folate One-Carbon Metabolism in Breast Cancer | Researchers showed that transgenic cyclin-dependent kinase 12 (CDK12) overexpression in the mouse mammary gland per se was sufficient to drive the emergence of multiple and multifocal tumors, while, in cooperation with known oncogenes, it promoted earlier tumor onset and metastasis.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
Loss of RBMS1 Promotes Anti-Tumor Immunity through Enabling PD-L1 Checkpoint Blockade in Triple-Negative Breast Cancer | Scientists reported that the RNA binding protein RBMS1 was prevalent among immune-cold TNBC and provided a new immunotherapeutic strategy against TNBC by targeting RBMS1.
[Cell Death & Differentiation] |
|
|
|
RUNX2 Recruits the NuRD(MTA1)/CRL4B Complex to Promote Breast Cancer Progression and Bone Metastasis | The authors demonstrated that the runt-related transcription factor 2 (RUNX2)/NuRD(MTA1)/cullin 4B-Ring E3 ligase (CRL4B) complex promoted the proliferation, invasion, tumorigenesis, bone metastasis, cancer stemness of breast cancer in vitro and in vivo.
[Cell Death & Differentiation] |
|
|
|
Halting ErbB-2 Isoforms Retrograde Transport to the Nucleus as a New Theragnostic Approach for Triple-Negative Breast Cancer | Investigators demonstrated that ErbB-2 was localized in the nucleus of TNBC cells and primary tumors, from where it drove growth.
[Cell Death & Disease] |
|
|
|
UBR5 Targets Tumor Suppressor CDC73 Proteolytically to Promote Aggressive Breast Cancer | Researchers demonstrated that CDC73 was a key substrate that impeded ubiquitin protein ligase E3 component n-recognin 5 (UBR5)’s profound tumorigenic and metastatic activities in TNBC.
[Cell Death & Disease] |
|
|
|
Radiobiological Effects of Wound Fluid on Breast Cancer Cell Lines and Human-Derived Tumor Spheroids in 2D and Microfluidic Culture | To clarify the effects of intraoperative radiotherapy-induced wound fluid on tumor progression, scientists treated breast cancer cell lines and human-derived tumor spheroids in 2D and microfluidic cell culture systems, respectively.
[Scientific Reports] |
|
|
|
The Dimerization of Methyl Vanillate Improves Its Effect against Breast Cancer Cells via Pro-oxidant Effect | The authors investigated the effects of methyl vanillate and methyl divanillate on breast cancer cell lines MCF-7 and MDA-MB-231 and compared the results using the non-tumor cell line HB4a.
[Chemico-Biological interactions] |
|
|
|
Parthenolide Reverses the Epithelial to Mesenchymal Transition Process in Breast Cancer by Targeting TGFbeta1: In Vitro and In Silico Studies | Scientists assessed the efficacy of parthenolide on epithelial to mesenchymal transition and its underlying mechanisms in both lowly metastatic, estrogen-receptor positive, MCF-7 cells and highly metastatic, triple-negative MDA-MB-231 cells.
[Life Sciences] |
|
|
|
Anti-Breast-Cancer Activity of Self-Fermented Bovistella sinensis Lloyd Extracts through the Mitochondrial ROS-Induced Apoptosis In Vitro | Dry fruiting body of Bovistella sinensis Lloyd was self-fermented to improve the anti-breast-cancer activity and the mitochondrial reactive oxygen species-induced apoptosis of key compounds was investigated.
[Journal of Food Biochemistry] |
|
|
|
Synergy between Sublethal Doses of Shikonin and Metformin Fully Inhibits Breast Cancer Cell Migration and Reverses Epithelial-Mesenchymal Transition | Researchers investigated the potential synergy between shikonin and anti-diabetic metformin against tumorigenic properties of breast cancer cell line MCF-7.
[Molecular Biology Reports] |
|
|
|
|
DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy | Investigators review the roles of DNA methyltransferase 3A (DNMT3A) and DNMT3B in breast tumorigenesis and development.
[Frontiers in Cell and Developmental Biology] |
|
|
|
Circular RNAs as Novel Biomarkers in Triple-Negative Breast Cancer: A Systematic Review | The authors focus on the abnormal expression of circRNAs and their diagnostic and prognostic values in TNBC.
[Molecular Biology Reports] |
|
|
|
|
Genzada Pharmaceuticals Opens Phase IB Metastatic Breast Cancer Trial | Genzada Pharmaceuticals USA, Inc. announced the official opening of a Phase IB clinical trial for the oral therapeutic GZ17-6.02 in combination with capecitabine in patients with metastatic breast cancer.
[Genzada Pharmaceuticals USA, Inc. (Digital Journal)] |
|
|
|
|
| September 19 – 20, 2022
Vejle, Denmark |
|
|
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Jülich Research Centre – Jülich, Germany |
|
|
|
| | Temple University – Philadelphia, Pennsylvania, United States |
|
|
|
| | Sidney Kimmel Cancer Center – Philadelphia, Pennsylvania, United States |
|
|
|
| | Luxembourg Institute of Health – Strassen, Luxembourg |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
